Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer
| Autor: | Ali Shamseddine, Nagi S. El Saghir, Azzam Dandashi, Buthaina Dabaja, Ziad Salem, Ali T. Taher |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Breast Neoplasms Neutropenia Vinorelbine Vinblastine Gastroenterology Drug Administration Schedule Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Aged Chemotherapy Leukopenia business.industry Liver Neoplasms Middle Aged medicine.disease Metastatic breast cancer Surgery Regimen Oncology Female medicine.symptom Cisplatin Neoplasm Recurrence Local business Progressive disease Febrile neutropenia medicine.drug |
| Zdroj: | American journal of clinical oncology. 22(3) |
| ISSN: | 0277-3732 |
| Popis: | The purpose of this study was to evaluate the combination of cisplatin and vinorelbine (PVn) for relapsed and chemotherapy-pretreated metastatic breast cancer. Twenty-three patients with metastatic breast cancer and prior chemotherapy were entered in a phase II study between June 1993 and December 1994. Eleven patients were premenopausal and 12 were postmenopausal. Follow-up data up to June 1997 are presented. All patients received cisplatin at a dose of 90 mg/m2 divided over 3 days as 30 mg/m2 infused over 4 hours. Intravenous vinorelbine 25 mg/m2 was given on days 1 and 8 or 15 according to patients' blood counts. Cycles were given every 3 to 4 weeks. An overall response rate of 61% (16/23 patients) was observed. Complete remission was obtained in six patients (26%) and partial remission was obtained in nine patients (35%). The duration of response ranged from 3 to 9 months, with an average of 4 months. Stable disease was noted in 29.1% and progressive disease in 8.3%. Overall survival at 12 months was 50%, and at 36 months it was 8%. Five of 12 patients (42%) who had prior doxorubicin therapy responded well to cisplatin-vinorelbine. Of those 12, seven were refractory and progressive on a doxorubicin-containing regimen, one had complete remission, and four had partial remission. Hematologic toxicity was acceptable. Treatment was delayed because of neutropenia in nine cycles (9.2%) and grade 2 leukopenia occurred in 54% of cycles. Febrile neutropenia occurred in seven cycles (7.1%), and five cycles were complicated by documented sepsis (5.1%). No treatment-related mortality occurred. Thrombocytopenia (grade 3) was seen in 27% of cycles, with no patient having a platelet count below 50,000 or bleeding episodes. Other toxicities were not major or dose-limiting. In conclusion, the combination of cisplatin and vinorelbine produced good responses: 61% response rate (16 of 23 patients) in relapsed, refractory, and heavily pretreated metastatic breast cancer, with 50% survival at 1 year, 12% at 2 years, and 8% at 3 years. In addition, a response rate of 42% (5 of 12 patients) was seen in patients resistant to anthracyclines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|